Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs DIVIS LABORATORIES - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA DIVIS LABORATORIES AUROBINDO PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 18.2 60.4 30.2% View Chart
P/BV x 3.9 13.9 28.3% View Chart
Dividend Yield % 0.3 0.4 60.8%  

Financials

 AUROBINDO PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
DIVIS LABORATORIES
Mar-19
AUROBINDO PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs8301,639 50.6%   
Low Rs5271,115 47.3%   
Sales per share (Unadj.) Rs333.9186.3 179.2%  
Earnings per share (Unadj.) Rs40.451.0 79.2%  
Cash flow per share (Unadj.) Rs51.857.3 90.3%  
Dividends per share (Unadj.) Rs2.5016.00 15.6%  
Dividend yield (eoy) %0.41.2 31.7%  
Book value per share (Unadj.) Rs237.1261.8 90.6%  
Shares outstanding (eoy) m585.91265.47 220.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.07.4 27.5%   
Avg P/E ratio x16.827.0 62.2%  
P/CF ratio (eoy) x13.124.0 54.6%  
Price / Book Value ratio x2.95.3 54.4%  
Dividend payout %6.231.4 19.7%   
Avg Mkt Cap Rs m397,569365,592 108.7%   
No. of employees `00017.911.8 150.7%   
Total wages/salary Rs m25,8495,423 476.7%   
Avg. sales/employee Rs Th10,956.94,175.1 262.4%   
Avg. wages/employee Rs Th1,447.7457.7 316.3%   
Avg. net profit/employee Rs Th1,324.31,141.8 116.0%   
INCOME DATA
Net Sales Rs m195,63649,463 395.5%  
Other income Rs m1,5531,556 99.8%   
Total revenues Rs m197,18951,019 386.5%   
Gross profit Rs m39,51918,718 211.1%  
Depreciation Rs m6,6801,689 395.5%   
Interest Rs m2,62635 7,502.9%   
Profit before tax Rs m31,76718,551 171.2%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,2695,023 144.7%   
Profit after tax Rs m23,64513,527 174.8%  
Gross profit margin %20.237.8 53.4%  
Effective tax rate %22.927.1 84.5%   
Net profit margin %12.127.3 44.2%  
BALANCE SHEET DATA
Current assets Rs m153,64546,501 330.4%   
Current liabilities Rs m120,4298,468 1,422.2%   
Net working cap to sales %17.076.9 22.1%  
Current ratio x1.35.5 23.2%  
Inventory Days Days135131 103.4%  
Debtors Days Days6486 74.2%  
Net fixed assets Rs m103,90925,797 402.8%   
Share capital Rs m586531 110.4%   
"Free" reserves Rs m138,32268,962 200.6%   
Net worth Rs m138,90869,493 199.9%   
Long term debt Rs m1,8000-   
Total assets Rs m264,54480,383 329.1%  
Interest coverage x13.1531.0 2.5%   
Debt to equity ratio x00-  
Sales to assets ratio x0.70.6 120.2%   
Return on assets %9.916.9 58.9%  
Return on equity %17.019.5 87.4%  
Return on capital %23.826.7 89.1%  
Exports to sales %49.60-   
Imports to sales %18.824.6 76.2%   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,74112,187 301.5%   
Fx inflow Rs m97,31641,238 236.0%   
Fx outflow Rs m40,58912,405 327.2%   
Net fx Rs m56,72728,833 196.7%   
CASH FLOW
From Operations Rs m16,2209,543 170.0%  
From Investments Rs m-28,768-6,854 419.7%  
From Financial Activity Rs m19,191-2,459 -780.3%  
Net Cashflow Rs m6,656230 2,899.1%  

Share Holding

Indian Promoters % 54.1 52.0 104.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 11.8 67.4%  
FIIs % 27.7 19.0 145.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 17.2 59.3%  
Shareholders   69,601 31,796 218.9%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  UNICHEM LAB  ALKEM LABORATORIES  CADILA HEALTHCARE  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex and Nifty Fell Over 1% Today(Closing)

Indian share markets witnessed heavy selling pressure today, pausing the record rally, with all sectors barring telecom, reeling under pressure.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 15, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS